A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis

Sponsor
International Extranodal Lymphoma Study Group (IELSG)
Study ID
NCT00210340
Phase
PHASE1
Status
Withdrawn

Conditions

  • Lymphoma, B Cell

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20+ non-Hodgkin's lymphomas.

Key Dates

Status verified
Mar 2015

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Safety profile of rituximab given intrathecally